New study tracks immune therapy results in advanced liver cancer

NCT ID NCT07321067

Not yet recruiting Knowledge-focused Sponsor: Ahmed Karam Helmy Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 75 adults with advanced liver cancer who are already receiving immune checkpoint inhibitors as part of their regular care. Researchers will track how long patients live and how long the cancer stays under control. The goal is to better understand the real-world effectiveness of these treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: immune checkpoint inhibitors (e.g., atezolizumab-bevacizumab, durvalumab-tremelimumab)
What this could lead to: If successful, this study could provide real-world data on how well these drugs work for advanced liver cancer, helping guide future treatment decisions.
What could go wrong: This is an observational study, not a controlled trial. Results may be limited by small size (75 people) and lack of a comparison group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Sohag university hospitals

Sohag, Sohag Governorate, 82511, Egypt
sSohag oncology centre

Sohag, Sohag Governorate, 82511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.